Glomerular Filtration Rate After Alpha-Radioimmunotherapy with211At-MX35-F(ab′)2: A Long-Term Study of Renal Function in Nude Mice-Reference-Cited by-同舟云学术

Glomerular Filtration Rate After Alpha-Radioimmunotherapy with211At-MX35-F(ab′)2: A Long-Term Study of Renal Function in Nude Mice

Published:2009-12 Issue:6 Volume:24 Page:649-658
ISSN:1084-9785
Container-title:Cancer Biotherapy and Radiopharmaceuticals
language:en
Short-container-title:Cancer Biotherapy and Radiopharmaceuticals

Author:

Bäck Tom¹,Haraldsson Börje²,Hultborn Ragnar³,Jensen Holger⁴,Johansson Martin E.⁵,Lindegren Sture¹,Jacobsson Lars¹

Affiliation:

1. Department of Radiation Physics, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.

2. Institute of Medicine, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden.

3. Department of Oncology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.

4. Cyclotron and PET Unit, Rigshospitalet, Copenhagen, Denmark.

5. Center for Molecular Pathology, Department of Laboratory Medicine, Lund University, University Hospital MAS, Malmö, Sweden.

Publisher

Mary Ann Liebert Inc

Subject

Cancer Research,Pharmacology,Radiology Nuclear Medicine and imaging,Oncology,General Medicine,Cancer Research,Pharmacology,Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://www.liebertpub.com/doi/pdf/10.1089/cbr.2009.0628

Reference31 articles.

1. Program and Abstracts Eleventh Conference on Cancer Therapy with Antibodies and Immunoconjugates

2. Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments

3. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab′ fragments

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In vitro and in vivo evaluation of a tetrazine-conjugated poly-L-lysine effector molecule labeled with astatine-211;EJNMMI Radiopharmacy and Chemistry;2024-05-22

2. Evaluation of targeting αVβ3 in breast cancers using RGD peptide-based agents;Nuclear Medicine and Biology;2024-01

3. Clinical Advances and Perspectives in Targeted Radionuclide Therapy;Pharmaceutics;2023-06-14

4. Astatine-211 based radionuclide therapy: Current clinical trial landscape;Frontiers in Medicine;2023-01-06

5. Recent progress of astatine-211 in endoradiotherapy: Great advances from fundamental properties to targeted radiopharmaceuticals;Chinese Chemical Letters;2022-07